Mode
Text Size
Log in / Sign up
Phase 3 N=4,994 Randomized Quadruple-blind Treatment

Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial

Transfusion · Age of Blood

Enrolled (actual)
4,994
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Mortality at Day 90 — 610; 594; 264; 259 participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Blood transfusion (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Australian and New Zealand Intensive Care Research Centre
Primary completion
Apr 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Mortality at Day 90
610; 594; 264; 259; 346; 335
SECONDARY
Mortality at Day 28
476; 463
SECONDARY
Persistent Organ Dysfunction Combined With Death Measured at Day 28
573; 549
SECONDARY
Days Alive and Free of Mechanical Ventilation
25; 25
SECONDARY
Day Alive and Free of Renal Replacement Therapy.
28; 22
SECONDARY
Blood Stream Infection in ICU (Post Randomisation)
123; 88
SECONDARY
Length of Stay in ICU and in Hospital Post Randomisation (Days)
4.2; 4.2; 14.5; 14.7
SECONDARY
Proportion of Patients Who Suffer at Least One Febrile Non-haemolytic Transfusion Reaction in ICU
35; 39
SECONDARY
EuroQol-5Dimension 5 Level (EQ-5D-5L) Score at Day 180 Post Randomisation

Summary

In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.

Eligibility Criteria

Inclusion Criteria

  • Patients hospitalised in ICU with an anticipated ICU stay of at least 24 hours, in whom the decision has been made by medical staff to transfuse at least one RBC unit.

Exclusion Criteria

  • Age younger than 18
  • Previous RBC transfusion during the current hospital admission (including transfusion in another hospital for transferred patients)
  • Diagnosis of transplantation or hematologic diseases
  • Pregnancy
  • Cardiac surgery during the present hospital admission
  • Expected to die imminently (<24hrs)
  • The treating physician believes it is not in the best interest of the patient to be randomised in this trial.
  • Known objection to the administration of human blood products
  • Participation in a competing study (see below)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01638416). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search